March 2, 2023 Conclusion of an agreement concerning the operational execution of Phase II of Phase I/II clinical trial of RVU120 in Patients with Relapsed/Refractory Solid Tumors
Read More
February 6, 2023 Receipt from a person discharging managerial responsibilities in the Company of a correction to the Article 19 MAR notification
Read More
February 3, 2023 Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
Read More
February 3, 2023 Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
Read More
January 26, 2023 Achievement of the first milestone under licence agreement with Exelixis Inc.
Read More
January 25, 2023 Announcement of the NDS on registration of series J shares with the NDS
Read More
January 25, 2023 Publication dates for periodic reports in 2023
Read More
January 25, 2023 Notification from TFI Allianz Polska S.A. of a change in its share in the total number of votes in the Company
Read More
January 20, 2023 Admission and introduction of the series J shares of the Company to trading on the regulated market of the WSE
Read More
January 20, 2023 Conditional registration of the series J shares of the Company with the National Depository for Securities
Read More
January 19, 2023 Notification from a shareholder of a change in its share in the total number of votes in the Company
Read More
January 18, 2023 Notification from a shareholder of a change in his share in the total number of votes in the Company
Read More
January 18, 2023 Registration of amendment of the Company’s Articles of Association concerning share capital
Read More
January 9, 2023 Notification from PTE Allianz Polska S.A. of a change in its share in the total number of votes in the Company
Read More
Posts navigation
